View Exam | PowerPak

1. According to the National Comprehensive Cancer Network Guidelines, for patients with chronic myeloid leukemia, the minimum goal for tyrosine kinase inhibitor treatment at 6 months is:

A. Complete hematologic response B. Partial cytogenetic response C. Complete cytogenetic response D. Major molecular response

2. AD is a 53-year-old female with chronic myeloid leukemia who has received imatinib 400 mg once a day for 1 year. She was switched to dasatinib 70 mg daily after cytogenetics (CG) showed more than 35% Ph-positive metaphases which continued for 1 year. During this current evaluation, CG showed 10% Ph-positive metaphases. She is evaluated for mutational analysis and is found to have a T315l mutation. Which of the following is the most appropriate next step in therapy for AD?

A. An allogeneic bone marrow transplant B. Switch to nilotinib 300 mg twice daily C. Switch to ponatinib 45 mg daily D. Increase dasatinib to 140 mg daily

3. LT is a 64-year-old man who was recently diagnosed with chronic myeloid leukemia. His medical history is notable for hypertension and chronic obstructive pulmonary disease. Which of the following tyrosine kinase inhibitors should be avoided given his medical history?

A. Dasatinib B. Nilotinib C. Omacetaxine D. Ponatinib

4. Which of the following statements regarding adherence to tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia is INCORRECT?

A. Missing more than 2 doses in 1 month is likely to affect response to therapy. B. A potential cost of nonadherence extends to increased use of chemotherapy and bone marrow transplants. C. A study showed that patients with higher copays were 42% more likely to be nonadherent. D. A study of long-term use of imatinib showed that less than 90% adherence significantly affected the probability of achieving a complete molecular response but not a major molecular response.

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. According to the National Comprehensive Cancer Network Guidelines, for patients with chronic myeloid leukemia, the minimum goal for tyrosine kinase inhibitor treatment at 6 months is:

3. LT is a 64-year-old man who was recently diagnosed with chronic myeloid leukemia. His medical history is notable for hypertension and chronic obstructive pulmonary disease. Which of the following tyrosine kinase inhibitors should be avoided given his medical history?

4. Which of the following statements regarding adherence to tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia is INCORRECT?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. According to the National Comprehensive Cancer Network Guidelines, for patients with chronic myeloid leukemia, the minimum goal for tyrosine kinase inhibitor treatment at 6 months is:

3. LT is a 64-year-old man who was recently diagnosed with chronic myeloid leukemia. His medical history is notable for hypertension and chronic obstructive pulmonary disease. Which of the following tyrosine kinase inhibitors should be avoided given his medical history?

4. Which of the following statements regarding adherence to tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia is INCORRECT?

« Return to Activity

Customers who Purchased
this Activity also Purchased